MyFinsight
Home
Blog
About
Issuance of common stock
under the atm offering...
$21,844K
Proceeds from long-term
debt, net of discount...
$19,259K
Issuance of common stock -
2020 espp
$1,125K
(30.81%↑ Y/Y)
Issuance of common stock
upon exercise of...
$111K
Maturities of marketable
securities
$87,646K
(-67.33%↓ Y/Y)
Net cash provided by
financing activities
$42,339K
(4811.72%↑ Y/Y)
Net cash provided by
investing activities
$25,544K
(41.16%↑ Y/Y)
Canceled cashflow
$62,091K
Net increase
(decrease) in cash and cash...
-$2,116K
(97.07%↑ Y/Y)
Canceled cashflow
$67,883K
Accrued and other
liabilities
$6,544K
(720.05%↑ Y/Y)
Stock-based compensation
expense
$5,884K
(-50.74%↓ Y/Y)
Depreciation and
amortization
$1,280K
(-42.26%↓ Y/Y)
Deferred revenue
$830K
(2962.07%↑ Y/Y)
Amortization of right-of-use
assets
$809K
(-43.23%↓ Y/Y)
Loss on disposal of
property and equipment
-$43K
Other non-current
assets
-$18K
(-100.35%↓ Y/Y)
Change in fair value of
derivative liability
$14K
(118.42%↑ Y/Y)
Purchase of marketable
securities
$62,036K
(-75.13%↓ Y/Y)
Acquisition of property and
equipment
$55K
(-92.11%↓ Y/Y)
Net cash used in
operating activities
-$69,999K
(23.19%↑ Y/Y)
Canceled cashflow
$15,422K
Net loss
-$72,936K
(28.93%↑ Y/Y)
Prepaid expenses and
other current assets
$6,532K
(93214.29%↑ Y/Y)
Accounts payable
-$4,058K
(-194.07%↓ Y/Y)
Net accretion of
discount on marketable...
$990K
(-59.31%↓ Y/Y)
Operating lease
liabilities
-$905K
(40.81%↑ Y/Y)
Back
Back
Cash Flow
4D Molecular Therapeutics, Inc. (FDMT)
4D Molecular Therapeutics, Inc. (FDMT)
source: myfinsight.com